🩺 A Doctor’s Note on India’s Pharma Trade Scrutiny

I’m deeply concerned—but also cautiously hopeful—about the recent anti‑dumping probe India has launched into imports of Ethambutol Hydrochloride, a key API used in TB drugs.

From a medical standpoint:

• Access to TB medicines is non-negotiable—we rely on affordable, consistent supply to treat vulnerable patients.

• But if imports are truly being “dumped” at unfairly low prices, it can undermine local pharma companies and potentially compromise long-term drug security.

• As a clinician, my priority is both quality and sustainability. If domestic manufacturing is hurt irreparably, we may face fragile supply chains for TB treatment.